Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld
R A
RA
Scripps Research Institute, Dept. of Immunology, La Jolla, CA 92037, USA.
Gillies
S D
SD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009447:Neuroblastoma / Q000276:immunology / Q000556:secondary / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins